Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
18655 Krause Street , Riverview, MI, 48193, US
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the entire drug life cycle. Leveraging an integrated network of facilities in North America, Europe, and India, we provide a comprehensive range of drug discovery services, early phase active pharmaceutical ingredient (API) and formulation development services, and late phase and commercial API and formulation services. We also offer specialized solutions for highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptides, potent solid oral drug products, vaccines, and biologics/bio-therapeutics.
Advances in payload-linker technology have made ADCs a major therapeutic modality, prompting drug developers to strive for greater selectivity and safety in the next wave of ADCs. Payload-linker selection is vital to these initiatives, making the choice of an experienced development and manufacturing partner a key decision in the highly competitive ADC market.
Released By Piramal Pharma Solutions
How Piramal Pharma is shaping resilient, patient-centric development across OSDs, HPAPIs, and sterile injectables.
From discovery to intermediates, APIs & drug products, a CDMO needs expertise across multiple elements of the pharma process to deliver an integrated experience
Enables more flexible and customizable dosing options for critical oral drug therapies, including modified release drug delivery.
By: Charlie Sternberg
The S&P Global CSA analyzes companies on environmental, social, and governance performance, governance maturity, and long-term value creation.
Underscores the facility’s dedication to upholding the highest standards of quality across operations.
Agreement expands Piramal’s payload-linker platform and bioconjugate abilities.
Provides the Morgpeth facility’s Formulation Development Team with an important tool for developing fixed dose combinations and modified release drug delivery.
The U.S. Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025.
The investment provides NewAmsterdam Pharma with commercial capacity for a fixed-dose combination of obicetrapib and ezetimibe to meet potential commercial demand.
The CDMO says the technology simplifies downstream processing for complex biologics.
By: Patrick Lavery
The role of a CDMO looked very different from what it has become today.
Released By Upperton
Site provides process R&D, analytical and stability testing, cGMP API manufacturing, and CMC support.
By: Kristin Brooks
AI and digital tools have potential to give timelines and quality a big boost, but CDMOs are aware of the inherent cautions.
From evolving strategic partnerships to emerging technologies and supply chain resiliency — learn how CDMOs are adapting to the new OSD manufacturing playbook.
Expands Quotient's capabilities for handling and manufacturing HPAPI drug molecules and products.
How Coperion’s single-source approach helps CDMOs and pharma manufacturers reduce complexity, accelerate scale-up, and support both batch and continuous operations.
Released By Coperion
Enters manufacturing pact with Recipharm aimed at expanding its contract development and manufacturing (CDMO) operations.
Why agility, scalability, and true collaboration are redefining biotech–CDMO relationships.
By: Nikki Whitfield
How partnerships, people, and technology will shape CDMO competitiveness in 2026.
By: Carsten Press
From new supply chain dynamics to emerging technologies and shifting regulatory standards— learn how CDMOs are adapting to the new API manufacturing playbook.
Psychedelics represent a fascinating class of compounds, ranging from naturally occurring molecules such as psilocybin and mescaline to synthetic analogues like LSD.
Jacquelyn Martin has more than 20 years of quality leadership experience in the pharmaceutical and CDMO sectors, with expertise spanning multiple modalities.
Its sterile CDMO business is expected to be online in the second half of 2026.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
